Mzuzu University Digital Repository

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis

Show simple item record

dc.contributor.author Chisale, Master R. O.
dc.contributor.author Ramazanu, Sheena
dc.contributor.author Mwale, Saul Eric
dc.contributor.author Kumwenda, Pizga
dc.contributor.author Chipeta, Mep
dc.contributor.author Kaminga, Atipatsa C.
dc.contributor.author Nkhata, Obed
dc.contributor.author Nyambalo, Billy
dc.contributor.author Chavura, Elton
dc.contributor.author Mbakaya, Balwani C.
dc.date.accessioned 2022-12-11T03:01:15Z
dc.date.available 2022-12-11T03:01:15Z
dc.date.issued 2021
dc.identifier.citation Chisale, M. O., Ramazanu, S., Mwale, S. E., Kumwenda, P., Chipeta, M., Kaminga, A. C., Nkhata, O., Nyambalo, B., Chavura, E. & Mbakaya, B. C. (2021). Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis. Reviews in medical virology, 32( 2), 1-10. https://doi.org/10.1002/rmv.2271 en_US
dc.identifier.uri https://doi.org/10.1002/rmv.2271
dc.identifier.uri http://repository.mzuni.ac.mw/handle/123456789/429
dc.description.abstract We estimated the seroprevalence of anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre‐prints that reported anti‐SARS‐CoV‐2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were eval uated using Joana Briggs Institute prevalence critical appraisal tool. Twenty‐three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa was 22% (95%CI: 14–31) with very high heterogeneity (I 2 = 100%, p < 0.001). Seroprevalence was highest in studies conducted in Central Africa compared to Southern Africa, West Africa, North Africa and East Africa respectively. The number of days between the first reported coronavirus disease 2019 case in each country and when a seropreva lence study was conducted was a significant moderator of seroprevalence. Sero positivity was numerically influenced by gender and age of the participants with males and those aged below 50 years being most affected with SARS‐CoV‐2 infection. The highest pooled seroprevalence in Africa reported in this review should be interpreted cautiously due to high heterogeneity between studies. Continued seroprevalence surveillance is warranted to establish Africa's transition towards herd immunity. en_US
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.title Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MzuniDR


Advanced Search

Browse

My Account